Yes, there is an increase in AS cases following Covid. There is a high incidence of post-viral arthralgia; the covid virus is well-known for producing inflammatory markers in the body, and we are ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin ...

By Hugo Francisco de Souza As Oropouche virus cases rise across South America, experts call for urgent action to prevent its ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

GlobalData’s report assesses the drugs in the Collagenase 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Objectives Although joint swelling is traditionally interpreted as synovitis, recent imaging studies showed that there is ...

There was higher prevalence of arthralgia and arthritis in the SS/RA group. Pulmonary involvement was also significantly more frequent in SS/RA group; 9/62 (14.5%) patients (six interstitial lung ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

Background Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major ...